Income, Indemnity and Business Continuity
Independent prescribing may allow a community pharmacy to provide a broader clinical service. It also changes the questions an owner, employed pharmacist or locum should ask about income, cover and continuity. The issue is not simply that national funding has been announced. It is whether the pharmacy can safely deliver the service, maintain appropriate cover, staff the model sustainably and explain its financial position.
What the 2026 to 2027 framework changes, and what it does not
England’s 2026 to 2027 Community Pharmacy Contractual Framework, or CPCF, provides total funding of £3.636 billion. This is £340 million above the total available in 2025 to 2026. Pharmacy First funding is now included within the CPCF budget. The framework also increases the single activity fee from £1.46 to £1.52, and says retained medicine margin will rise to £1.1 billion.[1]
Those are sector level arrangements, not a forecast of the profit, cash flow or personal income of an individual pharmacy. Each pharmacy’s result still depends on dispensing and service activity, medicine purchasing and margin experience, staffing, premises, systems, claims administration and other costs. National funding is relevant context, but it does not remove the need to test the pharmacy’s own figures.
From autumn 2026, the Department of Health and Social Care plans a national NHS independent prescribing offer as an extension of Pharmacy First and the pharmacy contraception service. The initial offer is intended to include prescribing in existing pathways, up to five new prescribing-only pathways subject to clinical reference group assessment, and appropriate circumstances for prescription management.[1]
The planned payment structure is summarised below. Read it alongside the relevant service terms, the regulations that take effect on 1 October 2026 and local onboarding requirements. It should not be treated as automatic income.[4]
| Payment or funding element | Announced arrangement | Planning point |
| Initial setup payment | A one-off £500 payment after the contractor has signed up and has a confirmed go-live date with an assured electronic prescribing service provider | It is conditional and not recurring profit.[1] |
| Monthly infrastructure payment | £525 each month during initial introduction | It does not establish that a service is profitable after staffing, training, system and operational costs.[1] |
| New prescribing-only pathway consultation | £17, matching the item of service fee for other Pharmacy First clinical pathways and minor illness consultations | Income depends on consultation activity delivered under the applicable pathway.[1] |
| Prescribing consultation in an existing pathway | £17 for Pharmacy First, £25 for initiation or ongoing contraception, and £20 for emergency hormonal contraception | A consultation fee is not the same as margin or net profit.[1] |
Independent prescribing clinical pathway consultations will count towards the existing Pharmacy First fixed payment thresholds. Those fixed payments remain £500 for 20 to 29 monthly consultations and £1,000 for 30 or more. Existing capping arrangements continue, with an additional allowance for contractors delivering independent prescribing clinical pathway consultations.[1] This reinforces the need to model activity, claims and capacity carefully rather than multiply a headline fee by an assumed volume.
Participation depends on readiness, onboarding and systems
The rollout is not a universal switch that turns on for every pharmacy in autumn. NHS England asked integrated care boards, or ICBs, to have a process by August 2026 to identify, approve and onboard pharmacies. Following the legal changes that take effect on 1 October 2026, ICBs are asked to onboard eligible pharmacies that have expressed an interest in becoming prescribing pharmacies under the CPCF.[2] [4]
NHS England expects ICBs to establish operational governance and oversee prescribing delivery. By 31 March 2027, at least 95% of onboarded pharmacies should be delivering prescriber-led consultations through agreed Pharmacy First and contraception pathways. All onboarded pharmacies should demonstrate prescribing activity through ePACT by that date.[2] These are system implementation objectives. They do not guarantee that an individual pharmacy will be onboarded, operating or earning a particular amount by a particular date.
An assured electronic prescribing service, or EPS, system is an important condition. The £500 setup payment requires a confirmed go-live date with such a provider. The framework states that regulatory changes for independent prescribing pharmacies conducting NHS clinical services include using an approved EPS system.[1] Technical readiness, governance, clinical protocols, workforce availability and claims processes are connected. A business plan should not assess any payment stream in isolation.
NHS England has allocated £51,000 per ICB or ICB cluster for 2026 to 2027 implementation activity, including approval of pharmacists and sites, cost centres, monitoring and governance. This is funding for ICB implementation work, not a payment to an individual pharmacy contractor.[2]
Keep new service income separate from business income
A pharmacy moving into prescribing may have dispensing-related revenue, medicine margin, Pharmacy First payments, contraception service payments, the one-off setup payment, the monthly infrastructure payment and prescribing consultation fees. These have different purposes, frequencies and conditions. Separating them in management information helps identify what is established, activity-linked, conditional or one-off.
For an employed pharmacist or locum, personal earnings can be different again from pharmacy service revenue. A payment to the contractor is not automatically a pay increase, a guaranteed shift pattern or reliable self-employed income. The written role, engagement terms and actual work pattern remain important evidence of personal income.
Plan for dependency on prescribing staff
The operational risk may be concentrated if one pharmacist is the only person able to provide prescribing consultations. Sickness, departure, parental leave, reduced hours or an inability to work could interrupt the service. It may affect appointment availability, activity and the ability to use infrastructure already put in place.
This is a key person risk question. It does not mean every prescribing pharmacist needs a particular product. It means the business should identify the role on which the service depends and decide how it would respond to an absence. Broadbench’s guide to key person insurance for medical practices explains the financial purpose of this type of cover. Consider whether another appropriately qualified prescriber is available, how scope and competence will be maintained, whether rotas provide sufficient cover, how patients will be redirected and who is accountable for service governance.
A continuity plan should separate clinical safety from financial resilience. Clinical arrangements may cover escalation, referral and patient communication. Business arrangements may include cash reserves, succession planning, appropriate cross-training and a review of financial exposure if a key person cannot work. The suitable response depends on the pharmacy’s ownership, workforce, service mix and professional advice.
Professional indemnity is not income or business protection
Professional indemnity concerns liabilities that can arise from professional work within the scope of the arrangement. The General Pharmaceutical Council, or GPhC, says pharmacy owners, employers, pharmacists and pharmacy technicians must have appropriate indemnity arrangements. It stresses that cover must match the work actually undertaken, rather than simply the job title.[3]
The GPhC advises checking whether cover explicitly extends to prescribing, patient group directions, undifferentiated diagnosis, supervision responsibilities and remote consultations. It advises professionals to contact their indemnity provider when roles or responsibilities change, and to retain written evidence of role changes, training and competency assessments.[3]
For locums, the message is direct. Do not assume an employer’s arrangements are sufficient. Ask what they cover and whether contingent indemnity is needed.[3] Employed pharmacists should likewise confirm the activity expected, the support available, the employer’s arrangements and any personal responsibility to arrange further cover. A provider, rather than this article, can confirm the scope and terms of an arrangement.
Income protection addresses a different financial question. It may help replace part of an individual’s income if illness or injury prevents them from working, subject to policy terms, eligibility and underwriting. It does not answer a claim arising from clinical work. Equally, professional indemnity does not replace personal earnings during a prolonged illness.
Business protection may address business-level financial consequences, but it has a different purpose from both professional indemnity and personal income protection. Key person arrangements, loan protection and shareholder or partnership arrangements can have distinct objectives. They should be considered with appropriate professional advice and against the actual ownership and borrowing structure. No form of cover guarantees that a pharmacy will keep trading or that all financial effects of an absence will be met.
Finance, acquisition and refinancing evidence
For a purchase, refinance or borrowing review, a lender or finance provider may need evidence explaining the established business and a planned service change. Broadbench’s article on buying your first clinical practice covers the wider acquisition and protection questions for a community pharmacy. Relevant evidence may include historic accounts, current management information, bank information, NHS payment statements or service claim records, premises and liabilities, workforce costs and a sustainable staffing plan. Where prescribing is relevant, record the onboarding status, prescribing capacity, operational assumptions and service activity.
The evidence is stronger when it separates established trading from a service that is planned or newly started. A budget should show what is historic, what is supported by evidence, and what remains an assumption. It should not present sector funding, a one-off setup payment or an ambitious consultation forecast as settled recurring profit. Lenders and finance providers make their own decisions. Their criteria, affordability assessment, security requirements and credit assessment can change.
Mortgage and borrowing warning: Your home may be repossessed if you do not keep up repayments on a mortgage or other loan secured on it. Borrowing for a pharmacy or other business can also place business assets and personal security at risk. Finance is subject to lender assessment, terms and affordability.
Prepare evidence before the service starts
A proportionate preparation file can support governance and financial discussions. Keep current accounts and management information, records that separate existing income streams, relevant NHS service and claim evidence, staffing plans, role descriptions and training records. Record the stage of ICB onboarding, EPS readiness, the contingency plan if prescribing capacity changes and the outcome of the indemnity review.
This is not about proving a future profit before the service exists. It is about showing what is confirmed, what is conditional and who carries each risk. That clarity can be valuable when speaking with an accountant, indemnity provider, insurer, finance provider or mortgage adviser.
Speak to Broadbench before decisions become urgent
Adding prescribing services or reviewing pharmacy finance? Speak to Broadbench about the borrowing and protection questions around your business model. We can help you prepare for a conversation about pharmacy finance, mortgages and protection, while recognising that lender and insurer decisions depend on evidence, eligibility, terms and assessment at the time.
Independent prescribing is an important planned change for community pharmacy in England. Prepare carefully. Keep national funding separate from individual profitability. Treat onboarding, EPS readiness and the relevant service terms as real conditions.[1] [2] [4] Match indemnity to the work undertaken. Plan for the loss of a key prescribing individual. Then keep financial evidence clear enough to distinguish established income from a service still being implemented.
References
[1] Department of Health and Social Care, Community Pharmacy Contractual Framework: financial year 2026 to 2027: https://www.gov.uk/government/publications/community-pharmacy-contractual-framework-financial-year-2026-to-2027/community-pharmacy-contractual-framework-financial-year-2026-to-2027
[2] NHS England, Preparing for prescribing in national community pharmacy services: https://www.england.nhs.uk/long-read/preparing-for-prescribing-in-national-community-pharmacy-services/
[3] General Pharmaceutical Council, Have you got the right indemnity arrangements?: https://www.pharmacyregulation.org/about-us/news-and-updates/regulate/have-you-got-right-indemnity-arrangements
[4] The National Health Service (Pharmaceutical and Local Pharmaceutical Services) (Amendment) (No. 2) Regulations 2026: https://www.legislation.gov.uk/uksi/2026/961/made
Speak to an expert